EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A phase 2 study of niraparib concomitant with tumor treating fields in patients with recurrent grade 4 glioma

Elizabeth C Cordell iD, Maikel Mansour, Austin R Pantel, Erin Schubert, Ali Nabavizadeh iD, Suyash Mohan iD, Eileen Maloney, Timothy Prior, Natalie Angeloni, Caroline Blessing, Suzanne Frangos, Leah Coghlan und 5 weitere

Neuro-Oncology Advances · 12.01.2026 · 8 (1)

DOI: 10.1093/noajnl/vdag076 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology Advances, online erschienen am 20.04.2026. Verfasst von Elizabeth C Cordell und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: GlaxoSmithKline and Novocure.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In preclinical models, tumor treating fields (TTFields) therapy promotes homologous repair deficiency (HRD), inducing potential sensitivity to poly (ADP-ribose) polymerase (PARP) inhibition. The aim of this study was to determine whether TTFields combined with the brain-penetrant PARP inhibitor niraparib has clinical efficacy in patients with recurrent high-grade glioma (HGG).

Methods

We conducted a phase 2 trial of TTFields therapy concomitant with niraparib in patients with glioblastoma (n = 7) or IDH-mutant grade 4 astrocytoma (n = 2) that was recurrent after prior radiotherapy. Cohort A was a single-arm primary efficacy cohort with the Simon’s 2-stage design. Cohort B was a surgical window-of-opportunity cohort in which TTFields were administered for 5-7 days prior to surgery and then resumed post-operatively with niraparib. The primary endpoint was disease control rate in cohort A, defined as objective response or stable disease (SD) lasting at least 16 weeks.

Results

The most common treatment-related adverse events were grade 1-2 dermatologic (scalp) toxicity in 67% of patients and grade 1-2 nausea in 67% of patients. In cohort A (n = 8), there were no objective responses, and 1 patient (12.5%) achieved SD lasting over 16 weeks. The efficacy benchmark to advance to Stage 2 was not achieved, and enrollment on Cohort A was terminated for futility. Cohort B (n = 1) was closed early due to slow accrual. In the single patient in Cohort B, TTFields-treated tumor tissue was negative for HRD.

Conclusions

The combination of niraparib and TTFields therapy for recurrent HGG was safe and well tolerated but did not demonstrate an efficacy signal.

Schlagwörter

Stichwörter der Autor:innen

IDH mutant gliomaPARP inhibitionglioblastomaniraparibtumor treating fields

Autor:innen und Institutionen

  • Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Department of Neurosurgery, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Department of Radiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.

ORCID-Profile: Elizabeth C Cordell, Ali Nabavizadeh, Suyash Mohan, E Paul Wileyto, Steven Brem, Stephen J Bagley

Förderung

  • GlaxoSmithKline and Novocure

Zitieren

APA

Cordell, E. C., Mansour, M., Pantel, A. R., Schubert, E., Nabavizadeh, A., Mohan, S., Maloney, E., Prior, T., Angeloni, N., Blessing, C., Frangos, S., Coghlan, L., Wileyto, E. P., O'Rourke, D. M., Brem, S., Desai, A. S., & Bagley, S. J. (2026). A phase 2 study of niraparib concomitant with tumor treating fields in patients with recurrent grade 4 glioma. Neuro-Oncology Advances, 8(1). https://doi.org/10.1093/noajnl/vdag076

Vancouver

Cordell EC, Mansour M, Pantel AR, Schubert E, Nabavizadeh A, Mohan S, et al. A phase 2 study of niraparib concomitant with tumor treating fields in patients with recurrent grade 4 glioma. Neuro-Oncology Advances. 2026;8(1). doi:10.1093/noajnl/vdag076

BibTeX
@article{Cordell2026,
  author = {Cordell, Elizabeth C and Mansour, Maikel and Pantel, Austin R and Schubert, Erin and Nabavizadeh, Ali and Mohan, Suyash and Maloney, Eileen and Prior, Timothy and Angeloni, Natalie and Blessing, Caroline and Frangos, Suzanne and Coghlan, Leah and Wileyto, E Paul and O'Rourke, Donald M and Brem, Steven and Desai, Arati S and Bagley, Stephen J},
  title = {A phase 2 study of niraparib concomitant with tumor treating fields in patients with recurrent grade 4 glioma},
  journal = {Neuro-Oncology Advances},
  year = {2026},
  volume = {8},
  number = {1},
  doi = {10.1093/noajnl/vdag076}
}
Kostenlos starten →